Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

doi:10.1158/1078-0432.CCR-16-1231

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2016

Thompson Jeffrey C, Yee Stephanie S, Troxel Andrea B, Savitch Samantha L, Fan Ryan, Balli David, Lieberman David B, Morrissette Jennifer D, Evans Tracey L, Bauml Joshua, Aggarwal Charu, Kosteva John A, Alley Evan, Ciunci Christine, Cohen Roger B, Bagley Stephen, Stonehouse-Lee Susan, Sherry Victoria E, Gilbert Elizabeth, Langer Corey, Vachani Anil, Carpenter Erica L

Abstract excerpt

PURPOSE: The expanding number of targeted therapeutics for non-small cell lung cancer (NSCLC) necessitates real-time tumor genotyping, yet tissue biopsies are difficult to perform serially and often yield inadequate DNA for next-generation sequencing (NGS). We evaluated the feasibility of using cell-free circulating tumor DNA (ctDNA) NGS as a complement or alternative to tissue NGS. EXPERIMENTAL DESIGN: A total...

Topics

Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Circulating Tumor DNA
DNA, Neoplasm
Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Female

Genotype

High-Throughput Nucleotide Sequencing

Humans

Lung Neoplasms

Male

Middle Aged

Mutation

Prospective Studies

Source

Open in PubMed Open full text

Identifiers

PMID: 27601595
DOI: 10.1158/1078-0432.CCR-16-1231
PMCID: PMC5448134

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.PMID 27601595Read ↗

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.Semantic proximity Read ↗

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumSemantic proximity Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR InhibitorSemantic proximity Read ↗

Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patientsSemantic proximity Read ↗

Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.Semantic proximity Read ↗

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung CancersSemantic proximity Read ↗

Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002Semantic proximity Read ↗

Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next-Generation Sequencing With Insufficient Tumor Samples.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.